Related Experiment Video
Updated: Jun 25, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Initial therapy in multiple myeloma: investigating the new treatment paradigm
Jacob K Kettle1, Karen L Finkbiner, Susan E Klenke
1Department of Pharmacy, University of Kansas Hospital, Kansas City, KS, USA.
Abstract:
The development of three novel chemotherapeutic agents - thalidomide, lenalidomide, and bortezomib - has resulted in a fundamental shift in the management of multiple myeloma. Despite this tremendous advancement, the selection of initial treatment must still be made with a degree of uncertainty as a true standard therapy has yet to be established. Although challenging, the relative abundance of therapeutic options, when taken into consideration with unique patient characteristics, creates the potential for individualization of care.For patients eligible for autologous stem cell transplantation, various combinations of novel agents with dexamethasone or traditional chemotherapy have supplanted the previous standard regimen consisting of vincristine, doxorubicin, and dexamethasone. In elderly patients or others that are deemed ineligible for the transplant procedure, the addition of a novel agent to melphalan-prednisone has demonstrated significant improvements in response rates. Due to the immaturity of the available data, it is perhaps best to regard the era of novel agents with a degree of rational enthusiasm, as the ultimate impact on patient care remains undetermined. Although further research is clearly implicated, recent advancements have resulted in significant progress toward obtaining optimum outcomes in a historically challenging disease.
Insights
Novel agents like thalidomide, lenalidomide, and bortezomib have transformed multiple myeloma treatment. While a standard therapy is not yet set, these advancements allow personalized care for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma management has been revolutionized by novel chemotherapeutic agents.
- Despite advancements, a definitive standard therapy remains elusive, necessitating individualized treatment approaches.
- Patient characteristics play a crucial role in selecting optimal therapeutic strategies.
Purpose of the Study:
- To review the impact of novel agents on multiple myeloma treatment.
- To discuss the evolving landscape of therapeutic options and personalized care.
- To highlight the progress and future directions in managing multiple myeloma.
Main Methods:
- Review of recent clinical advancements and therapeutic strategies in multiple myeloma.
- Analysis of treatment regimens for patients eligible and ineligible for autologous stem cell transplantation.
- Evaluation of the role of novel agents (thalidomide, lenalidomide, bortezomib) in combination therapies.
Main Results:
- Novel agents have largely replaced older regimens in transplant-eligible patients.
- Combination therapies including novel agents show improved response rates in transplant-ineligible patients.
- Individualized treatment selection is facilitated by the availability of diverse therapeutic options.
Conclusions:
- The introduction of novel agents marks a significant shift in multiple myeloma management.
- While promising, the long-term impact of these agents requires further investigation.
- Continued research is essential to optimize outcomes for patients with multiple myeloma.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...